The use of a UTMD‐mediated BMP9 intra‐tumoural delivery system might improve cytotoxic lymphocyte infiltration by normalising the tumour vasculature, leading to the potentiation of immunotherapy with ICBs. This evidence concerns the gene GDF2 and neoplasm.